S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation|
|GenSpera, Inc. (GNSZ) Releases Updated Corporate Video: "GenSpera has targeted its active ingredient thapsigargin to kill only the cells we select: cancer"|
|GenSpera CEO, Craig Dionne, to Present Update on Lead Drug Candidate G-202 at 2014 Bio International Convention|
|GenSpera Announces US Patent for Methods and Compositions for the Detection, Imaging and Treatment of Cancer|
|Media Advisory: GenSpera 2014 BIO International Presentation Available|
|GenSpera Releases 2014 BIO International Presentation and HCC Clinical Trial Update for G-202|
|GenSpera Presents G-202 HCC Clinical Trial Update at 5th Asia-Pacific Primary Liver Cancer Expert Meeting|
|GenSpera To Present Ongoing HCC Trial Data at APPLE 2014 Congress July 12th in Taipei|
|Media Advisory: GenSpera's G-202 HCC Clinical Trial Presentation from 5th Asia-Pacific Primary Liver Cancer Expert (APPLE) Meeting Available|
|GenSpera's CEO Shares Insight on Unique Properties and Targeting of Lead Drug G-202, Based on the Thapsigargin Toxin|
Click above to view more mutual fund data and stats for gnsz - Genspera Inc.